Phase 2 N=96 Normobaric Hyperoxia for Intracerebral Hemorrhage
Normobaric Hyperoxia · Intracerebral Hemorrhage
Primary: Percentage of Patients With mRS 0-3 — 39; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Oxidative Stress and Surgical Recovery
Surgical Recovery · Pain, Postoperative
Primary: Phosphorylation of STAT-3 in MDSC (Myeloid-derived Suppressor Cells) — 2.162; 2.025 STAT3 archsinh ratio — p=0.5490
Phase 2 N=18 Ga-DOTATATE PET for Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
Osteomalacia
Primary: Number of Participants With Positive Localization of Phosphaturic Mesenchymal Tumors (PMTs) — 15 Participants
Phase 2 N=178 Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recurrent Ovarian Cancer · Recurrent Fallopian Tube Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 5.29; 5.55; 3.76 months — p=0.3293
Phase 2 N=51 Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Solid Tumor · Solid Carcinoma · Solid Tumor, Adult
Primary: Percent Reduction in CTCAE Grade 2/3 Eosinophil-related Cutaneous Adverse Events — 32; 10; 9 Participants
Phase 2 N=50 Scopolamine in Bipolar Depression
Bipolar Disorder Depression
Primary: Hamilton Depression Rating Scale Score After Last Treatment — 12.0; 13.0 units on a scale — p=0.3
Phase 2 N=187 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Part A: Change From Baseline in Body Weight at Week 12 — NA; NA; NA; NA Kilogram
Phase 2 N=100 Cold-stored Platelet Early Intervention in TBI
Traumatic Brain Injury
Primary: Study Feasibility — 50; 50 Participants
Phase 2 N=25 MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Part 1 and Part 2: Number of Participants Experiencing Treatment-emergent Adverse Events — 2; 3; 3; 6 Participants
Phase 2 N=52 Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
Metastatic Prostatic Adenocarcinoma
Primary: PSA Response at 10 Months — 15 Participants
Phase 2 N=6 Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
Variegate Porphyria
Primary: The Change in Disease Severity in Patients With VP as Measured by CGIC. — 2.5 Scores on a scale
Phase 2 N=217 Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103) — 119 Participants
Phase 2 N=88 Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia
Pregnancy Related
Primary: Pain Burden, AUC (30 Minutes) — 101; 67; 39 pain units*minutes — p=0.226
Phase 2 N=178 AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
Cervical Cancer
Primary: Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive Participants — 26.2 percentage of participants — p=0.0054
Phase 2 N=24 Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury
Spinal Cord Injuries
Primary: Brief Pain Inventory, Worst Pain — 8.9; 9.7 score on scale